Atlas Trials

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

Clinical trial NCT02973503 · COMPLETED

Trial details

NCT number
NCT02973503
Sponsor
University Hospital, Clermont-Ferrand
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic HCV Infection
Start date
2017-01-11
Primary completion
2018-11-10
Enrollment
117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.